In Brief: Chiron Vaccines
Chiron Vaccines: Magnus Lundberg to president, replacing Dino Dina who has resigned from the company. Lundberg, 40, who is president of Chiron Therapeutics, joined Chiron from Pharmacia & Upjohn in April 1996, where he was head of metabolic diseases. "Dino, whose background is in research and business strategy, elected to step aside in favor of more experienced commercial management," the company said...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth